BofA reiterates Buy on Kura Oncology despite insider selling
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Kura Oncology with a $31.00 price target. The call comes despite negative insider sentiment, with increased insider selling over the past quarter, including a recent sale by the COO. Kura reported higher quarterly revenue but a wider GAAP net loss year over year.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.